These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7858910)

  • 1. The role of apolipoprotein A-I-containing lipoproteins in atherosclerosis.
    Forte TM; McCall MR
    Curr Opin Lipidol; 1994 Oct; 5(5):354-64. PubMed ID: 7858910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein A-I-containing lipoproteins and atherosclerosis.
    Leroy A; Dallongeville J; Fruchart JC
    Curr Opin Lipidol; 1995 Oct; 6(5):281-5. PubMed ID: 8520850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased cholesterol efflux in apolipoprotein AI (ApoAI)-producing macrophages as a mechanism for reduced atherosclerosis in ApoAI((-/-)) mice.
    Major AS; Dove DE; Ishiguro H; Su YR; Brown AM; Liu L; Carter KJ; Linton MF; Fazio S
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1790-5. PubMed ID: 11701467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk.
    Fruchart JC; De Geteire C; Delfly B; Castro GR
    Atherosclerosis; 1994 Oct; 110 Suppl():S35-9. PubMed ID: 7857382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein A-II, HDL metabolism and atherosclerosis.
    Tailleux A; Duriez P; Fruchart JC; Clavey V
    Atherosclerosis; 2002 Sep; 164(1):1-13. PubMed ID: 12119188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles.
    Castellani LW; Navab M; Van Lenten BJ; Hedrick CC; Hama SY; Goto AM; Fogelman AM; Lusis AJ
    J Clin Invest; 1997 Jul; 100(2):464-74. PubMed ID: 9218525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice.
    Schultz JR; Verstuyft JG; Gong EL; Nichols AV; Rubin EM
    Nature; 1993 Oct; 365(6448):762-4. PubMed ID: 8413656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits.
    Zhang J; Niimi M; Yang D; Liang J; Xu J; Kimura T; Mathew AV; Guo Y; Fan Y; Zhu T; Song J; Ackermann R; Koike Y; Schwendeman A; Lai L; Pennathur S; Garcia-Barrio M; Fan J; Chen YE
    Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1068-1075. PubMed ID: 28428219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
    Moore RE; Navab M; Millar JS; Zimetti F; Hama S; Rothblat GH; Rader DJ
    Circ Res; 2005 Oct; 97(8):763-71. PubMed ID: 16151025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
    Holvoet P; Danloy S; Deridder E; Lox M; Bernar H; Dhoest A; Collen D
    J Clin Invest; 1998 Jul; 102(2):379-85. PubMed ID: 9664079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice.
    Chiesa G; Parolini C; Canavesi M; Colombo N; Sirtori CR; Fumagalli R; Franceschini G; Bernini F
    Arterioscler Thromb Vasc Biol; 1998 Sep; 18(9):1417-23. PubMed ID: 9743230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lipoproteins].
    Manso C
    Rev Port Cardiol; 1991 Feb; 10(2):155-70. PubMed ID: 2059473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of human apolipoprotein A-I and high density lipoproteins in transgenic mice do not enhance efflux of cholesterol from a depot of injected lipoproteins. Relevance to regression of atherosclerosis?
    Stein O; Dabach Y; Hollander G; Ben-Naim M; Halperin G; Stein Y
    Atherosclerosis; 1999 Jun; 144(2):367-74. PubMed ID: 10407497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport.
    von Eckardstein A; Nofer JR; Assmann G
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):13-27. PubMed ID: 11145929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
    Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of apolipoprotein O does not impact on plasma HDL levels or functionality in human apolipoprotein A-I transgenic mice.
    Nijstad N; de Boer JF; Lagor WR; Toelle M; Usher D; Annema W; der Giet Mv; Rader DJ; Tietge UJ
    Biochim Biophys Acta; 2011 Apr; 1811(4):294-9. PubMed ID: 21296681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.
    Warden CH; Hedrick CC; Qiao JH; Castellani LW; Lusis AJ
    Science; 1993 Jul; 261(5120):469-72. PubMed ID: 8332912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
    Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
    Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High density lipoproteins and coronary heart disease.
    Barter PJ; Rye KA
    Atherosclerosis; 1996 Mar; 121(1):1-12. PubMed ID: 8678914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.